MSH|^~\&#|NIST EHR|NIST EHR Facility|NIST Test Lab APP|NIST Lab Facility|20130211184101-0500||OML^O21^OML_O21|NIST-LOI_8.0_1.1-NG|T|2.5.1|||AL|AL|||||LOI_Common_Component^LOI Base Profile^2.16.840.1.113883.9.66^ISO~LOI_NG_Component^LOI NG Profile^2.16.840.1.113883.9.79^ISO~LAB_PRU_Component^LOI PRU Profile^2.16.840.1.113883.9.82^ISOPID|1||PATID5678^^^NIST MPI^MR||Vannatatu^Yolanda^G.^^^^L||19281011|F||2076-8^Native Hawaiian or Other Pacific Islander^HL70005|15006 Bloomquist Way^Apt 4^Huntington Park^CA^90255^^H|||||||||||H^Hispanic^HL70189ORC|NW|ORD798642-1^Lamaze EHR||ORD798642^Lamaze EHR|||||20130124|||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has been informed of responsibility, and agrees to pay for service^HL70339OBR|1|ORD798642-1^Lamaze EHR||24323-8^Comprehensive metabolic 2000 panel - Serum or Plasma^LN^^^^2.42^^Comprehensive Metabolic profile|||201301240820-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI|^^PH^^^626^9876543^1DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||||2DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3SPM|1|SP798642-1&Lamaze EHR||119364003^Serum specimen (specimen)^SCT^SER^Serum^L|||||||||||||201301240820-0800ORC|NW|ORD798642-2^Lamaze EHR||ORD798642^Lamaze EHR|||||20130124|||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has been informed of responsibility, and agrees to pay for service^HL70339OBR|2|ORD798642-2^Lamaze EHR||57021-8^CBC W Auto Differential panel in Blood^LN^^^^2.42^^CBC W Auto Differential panel in Blood|||201301240825-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI|^^PH^^^626^9876543^1DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||||2DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3SPM|1|SP798642-2&Lamaze EHR||119297000^Blood Specimen^SCT^BLD^Blood^L|||||||||||||201301240825-0800ORC|NW|ORD798642-3^Lamaze EHR||ORD798642^Lamaze EHR|||||20130124|||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has been informed of responsibility, and agrees to pay for service^HL70339OBR|3|ORD798642-3^Lamaze EHR||59261-8^Hemoglobin A1c/Hemoglobin.total in Blood^LN^^^^2.42^^Hemoglobin A1c NGSP protocol in blood|||201301240825-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI|^^PH^^^626^9876543^1DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||||2DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3SPM|1|SP798642-2&Lamaze EHR||119297000^Blood Specimen^SCT^BLD^Blood^L|||||||||||||201301240825-0800ORC|NW|ORD798642-4^Lamaze EHR||ORD798642^Lamaze EHR|||||20130124|||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has been informed of responsibility, and agrees to pay for service^HL70339OBR|4|ORD798642-4^Lamaze EHR||1554-5^Glucose [Mass/volume] in Serum or Plasma --12 hours fasting^LN^^^^2.42^^Glucose 12 hr fasting|||201301240820-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI|^^PH^^^626^9876543^1DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||||2DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3OBX|1|CWE|49541-6^Fasting status^LN^1902^Fasting Status^99USL||Y^Yes^HL70136||||||O|||20130124|||||||||||||||SCISPM|1|SP798642-1&Lamaze EHR||119364003^Serum specimen (specimen)^SCT^SER^Serum^L|||||||||||||201301240820-0800ORC|NW|ORD798642-5^Lamaze EHR||ORD798642^Lamaze EHR|||||20130124|||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has been informed of responsibility, and agrees to pay for service^HL70339OBR|5|ORD798642-5^Lamaze EHR||24331-1^Lipid 1996 panel in Serum or Plasma^LN^^^^2.42^^Lipid 1996 panel in Serum or Plasma|||201301240825-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI|^^PH^^^626^9876543^1DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||||2DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3OBX|1|CWE|49541-6^Fasting status^LN^1902^Fasting Status^99USL||Y^Yes^HL70136||||||O|||20130124|||||||||||||||SCISPM|1|SP798642-2&Lamaze EHR||119297000^Blood Specimen^SCT^BLD^Blood^L|||||||||||||201301240825-0800ORC|NW|ORD798642-6^Lamaze EHR||ORD798642^Lamaze EHR|||||20130124|||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has been informed of responsibility, and agrees to pay for service^HL70339OBR|6|ORD798642-6^Lamaze EHR||50564-4^Urinalysis panel - Urine by Auto^LN^^^^2.42^^Complete UA - Auto|||201301240840-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI^L^^^NPI|^^PH^^^626^9876543^1DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||||2DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3SPM|1|SP798642-3&Lamaze EHR||258574006^Midstream Urine^SCT^URMS^Urine, midstream^L|||||||||||||201301240840-0800